New Jersey is the latest US state to pass a law that will allow the substitution of biosimilars at the pharmacy level, the Generics and Biosimilars Initiative (GaBI) is reporting. New Jersey Governor Chris Christie signed Assembly Bill 2477 into law on November 9, 2015, following unanimous passage in the New Jersey Senate and Assembly earlier in the year. The New Jersey bill authorizes a pharmacist to substitute a biosimilar for a prescribed biological product if the biosimilar has been approved by FDA as interchangeable and the prescriber has not indicated “do not substitute.” To date, 15 states have passed legislation allowing for substitution of biosimilars: ● California ● Colorado ● Delaware ● Florida ● Georgia ● Indiana ● Massachusetts ● New Jersey ● North Carolina ● North Dakota ● Tennessee ● Texas ● Utah ● Virginia, and ● Washington.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
